Roble, Belko & Company, Inc Astrazeneca PLC Transaction History
Roble, Belko & Company, Inc
- $634 Million
- Q3 2024
A detailed history of Roble, Belko & Company, Inc transactions in Astrazeneca PLC stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 314 shares of AZN stock, worth $20,818. This represents 0.0% of its overall portfolio holdings.
Number of Shares
314
Previous 314
-0.0%
Holding current value
$20,818
Previous $24,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AZN
# of Institutions
1,361Shares Held
475MCall Options Held
5.39MPut Options Held
3.75M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.17 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$2.78 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.47 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.44 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.1MShares$1.27 Billion0.45% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $205B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...